PD-1 Monotherapy Reigns Supreme in Adjuvant Melanoma…But for How Long?
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 37378689.
- Also identified by DOI 10.1158/1078-0432.CCR-23-1194 and PMC identifier 10527539.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The results of CheckMate-238 led to the original FDA approval of anti-PD-1 therapy in high-risk, resectable melanoma. In this CCR Translations, we discuss the 5-year update of this pivotal trial and contextualize its results in the face of limited survival data, neoadjuvant therapy, next-generation biomarkers, and novel immunotherapy combinations. See related article by Larkin et al., p. 3352.
Medical subject headings
- Nivolumab
- Melanoma